Iverscab Z 6mg/400mg Tablet is a combination antiparasitic medication containing Ivermectin 6mg and Albendazole 400mg, indicated for the treatment of a variety of parasitic infections. Ivermectin acts by binding selectively to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to paralysis and death of the parasites. Albendazole, a broad-spectrum anthelmintic, inhibits microtubule synthesis by binding to beta-tubulin, disrupting essential cellular processes in helminths. This synergistic combination is effective against a wide range of intestinal and tissue parasites including strongyloidiasis, ascariasis, trichuriasis, hookworm infections, and neurocysticercosis. The tablet is typically administered orally, with dosage and duration tailored according to the specific parasitic infection and patient factors such as age and weight. Iverscab Z is generally well tolerated; however, adverse effects may include gastrointestinal disturbances, dizziness, headache, and transient elevations in liver enzymes. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with hypersensitivity to either component. This medication should be used under medical supervision, with appropriate diagnostic confirmation and follow-up to ensure efficacy and monitor for potential side effects.